RecruitingPhase 3

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Japan450 participantsStarted 2022-07-21

Plain-language summary

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia

Age range18 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Received 2 or more antipsychotics, each at doses equivalent to ≥ 600 mg/day of chlorpromazine
✕. Received a mean daily dose equivalent to \> 800 mg/day\*\*,\*\*\* of chlorpromazine

Mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at last visit of the double-blind period

Timeframe: Baseline and Week 7

NCT IDNCT05325645

SponsorOtsuka Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-02

Drug Information Center